Form 144: EW insider plans sale of 8,950 shares via Schwab

Rhea-AI Filing Summary

Edwards Lifesciences (EW) Form 144 notice: An insider proposes a routine sale of 8,950 common shares through Charles Schwab & Co., with an aggregate market value of $698,679.00. The shares were acquired on 08/18/2025 via an employee stock option exercise and the planned sale date is listed as 08/18/2025. The filer previously sold 8,950 shares on 06/16/2025 for gross proceeds of $673,268.00. Outstanding shares are listed as 587,100,000, making this transaction immaterial relative to total shares outstanding.

Insights

Securities Analyst

TL;DR: Routine insider sale disclosed; size is immaterial versus shares outstanding.

The Form 144 shows an insider exercising options and proposing an immediate, cashless sale of 8,950 shares through Charles Schwab. At an aggregate value of $698,679 against 587.1 million shares outstanding, this sale is immaterial to company capitalization and unlikely to affect market dynamics. The filing satisfies disclosure requirements and records a prior similar sale on 06/16/2025, indicating recurring limited monetization by the holder.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 obligations; no governance red flags apparent.

The notice documents an employee stock option exercise followed by a cashless broker-assisted sale reported under Rule 144. The filer affirms lack of undisclosed material adverse information. There is no indication of unusual timing, large block sales, or use of a Rule 10b5-1 plan. From a governance perspective, the filing represents standard insider liquidity rather than a signal of governance stress.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	8950	698679.00	587100000	08/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/18/2025	Employee Stock Option Exercise	EDWARDS LIFESCIENCES CORPORATION			8950	08/18/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Larry L Wood ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	06/16/2025	8950	673268.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for Edwards Lifesciences (EW) disclose?

The notice discloses a proposed sale of 8,950 common shares via Charles Schwab with an aggregate market value of $698,679.00, acquired and to be sold on 08/18/2025.

How significant is the 8,950-share sale relative to EW's outstanding shares?

The filing lists 587,100,000 shares outstanding, so 8,950 shares are immaterial as a percentage of total shares outstanding.

How were the shares acquired according to the filing?

The shares were acquired via an employee stock option exercise on 08/18/2025 with a cashless broker payment.

Has the filer sold EW shares recently?

Yes. The filer sold 8,950 shares on 06/16/2025 for gross proceeds of $673,268.00.

Which broker is handling the proposed sale?

The proposed sale is to be executed through Charles Schwab & Co., Inc.